BACKGROUND Infiltrating ductal breast carcinoma with monoclonal gammopathy of undetermined significance(MGUS)is rare and easily misdiagnosed.Most patients are first diagnosed with MGUS.We report a rare case of MGUS se...BACKGROUND Infiltrating ductal breast carcinoma with monoclonal gammopathy of undetermined significance(MGUS)is rare and easily misdiagnosed.Most patients are first diagnosed with MGUS.We report a rare case of MGUS secondary to infiltrating ductal breast carcinoma.We also review the literature to analyze the clinical characteristics and diagnostic methods.CASE SUMMARY A 51-year-old woman underwent modified radical mastectomy for infiltrating ductal carcinoma of the right breast and was then treated with radiation and chemotherapy.A decreased platelet count was found on routine blood examination,and MGUS was subsequently diagnosed.This is the first report of the occurrence of MGUS after breast cancer surgery.CONCLUSION Vigilance is required to distinguish this rare comorbidity from breast plasmacytoma.展开更多
Background: Ankylosing spondylitis (AS) is a chronic inflammatory disease which is characterized by the involvement of the sacroiliac joint and the spine, the main therapy includes biological agents, which may increas...Background: Ankylosing spondylitis (AS) is a chronic inflammatory disease which is characterized by the involvement of the sacroiliac joint and the spine, the main therapy includes biological agents, which may increase the risk of tumor and infection in long term application. Case Presentation: A fifty-year- old man was diagnosed of AS. He received the therapy of golimumab 50 mg once every one month subcutaneously. After receiving this treatment for two years and eight months, the patient had an elevated level of IgA. The monoclonal protein was finally identified as the type of IgA-kappa from the immunofixation study. Bone marrow aspirate smear revealed infiltration by plasma cells (5%) and immunophenotyping was positive for CD27, CD28, CD38, CD45, CD138 and cKappa, which was finally diagnosed of MGUS. Conclusion: This case demonstrates that golimumab may increase the risk of premalignant disease in patients with AS. With our case report, we also like to highlight that patients with AS may have increased risk of plasma cell malignancies.展开更多
Aim:Health care insurance improves access to care and thus outcome in patients with solid tumors.Little information on the impact of health care insurance on hematological malignancies including multiple myeloma exist...Aim:Health care insurance improves access to care and thus outcome in patients with solid tumors.Little information on the impact of health care insurance on hematological malignancies including multiple myeloma exists.The authors aimed to analyze the effect of health care insurance on the survival of patients with multiple myeloma(MM)and monoclonal gammopathy of undetermined significance(MGUS)at Louisiana State University Health Sciences Center in Shreveport,LA.Methods:Two hundred fifty seven patients were reviewed,of which 208 had MM and 49 had MGUS.Results:One hundred and seventy seven patients(69%)were funded and 80(31%)were non-funded.Funded patients with MM had an overall survival(OS)of 6.2 years compared to 3.8 years for non-funded patients(P<0.001).Survivals were not significantly affected by race or gender.The analysis demonstrates that funded patients with MM and MGUS patients have statistically significant increased OS compared to patients with no insurance.Conclusion:This study showed that patients with multiple myeloma and MGUS with health care insurance have longer overall survival when compared to non-funded patients.展开更多
基金The Second Batch of Qinghai Province“Thousand talents Plan for High-end Innovative Talents,”No.[2017]5.
文摘BACKGROUND Infiltrating ductal breast carcinoma with monoclonal gammopathy of undetermined significance(MGUS)is rare and easily misdiagnosed.Most patients are first diagnosed with MGUS.We report a rare case of MGUS secondary to infiltrating ductal breast carcinoma.We also review the literature to analyze the clinical characteristics and diagnostic methods.CASE SUMMARY A 51-year-old woman underwent modified radical mastectomy for infiltrating ductal carcinoma of the right breast and was then treated with radiation and chemotherapy.A decreased platelet count was found on routine blood examination,and MGUS was subsequently diagnosed.This is the first report of the occurrence of MGUS after breast cancer surgery.CONCLUSION Vigilance is required to distinguish this rare comorbidity from breast plasmacytoma.
文摘Background: Ankylosing spondylitis (AS) is a chronic inflammatory disease which is characterized by the involvement of the sacroiliac joint and the spine, the main therapy includes biological agents, which may increase the risk of tumor and infection in long term application. Case Presentation: A fifty-year- old man was diagnosed of AS. He received the therapy of golimumab 50 mg once every one month subcutaneously. After receiving this treatment for two years and eight months, the patient had an elevated level of IgA. The monoclonal protein was finally identified as the type of IgA-kappa from the immunofixation study. Bone marrow aspirate smear revealed infiltration by plasma cells (5%) and immunophenotyping was positive for CD27, CD28, CD38, CD45, CD138 and cKappa, which was finally diagnosed of MGUS. Conclusion: This case demonstrates that golimumab may increase the risk of premalignant disease in patients with AS. With our case report, we also like to highlight that patients with AS may have increased risk of plasma cell malignancies.
文摘Aim:Health care insurance improves access to care and thus outcome in patients with solid tumors.Little information on the impact of health care insurance on hematological malignancies including multiple myeloma exists.The authors aimed to analyze the effect of health care insurance on the survival of patients with multiple myeloma(MM)and monoclonal gammopathy of undetermined significance(MGUS)at Louisiana State University Health Sciences Center in Shreveport,LA.Methods:Two hundred fifty seven patients were reviewed,of which 208 had MM and 49 had MGUS.Results:One hundred and seventy seven patients(69%)were funded and 80(31%)were non-funded.Funded patients with MM had an overall survival(OS)of 6.2 years compared to 3.8 years for non-funded patients(P<0.001).Survivals were not significantly affected by race or gender.The analysis demonstrates that funded patients with MM and MGUS patients have statistically significant increased OS compared to patients with no insurance.Conclusion:This study showed that patients with multiple myeloma and MGUS with health care insurance have longer overall survival when compared to non-funded patients.
